Source
25 articles citing this source
With the Stratos direct air capture facility in Texas targeting Q2 startup, California's first CCS project nearing injection, and Norway's Northern Lights expanding, the carbon capture industry is transitioning from pilot projects to commercial-scale operations in 2026.
Fervo Energy closed a $421 million non-recourse financing package for its flagship Cape Station enhanced geothermal project in Utah, with first power expected in 2026 and an IPO filing reportedly underway.
Norwegian startup Flocean is preparing to launch Flocean One, the world's first commercial subsea desalination plant, at Mongstad in Q2 2026, using deep-ocean pressure to cut energy use by up to 50 percent.
MariaDB will merge its relational database with GridGain's in-memory computing platform to target latency-sensitive agentic AI workloads, marking the company's third acquisition in nine months under private equity ownership.
Munich-based Proxima Fusion, RWE, Bavaria, and the Max Planck Institute for Plasma Physics have agreed on a two-stage, multibillion-euro roadmap to build a demonstration stellarator and a grid-connected commercial fusion plant at the decommissioned Gundremmingen reactor site.
Takeda's oveporexton, an oral drug that restores the brain chemical missing in narcolepsy type 1, has received FDA priority review after two Phase 3 trials showed it brought patients to near-normal wakefulness and cut cataplexy episodes by more than 80 percent.
Precision BioSciences receives FDA Fast Track for PBGENE-DMD, a gene-editing therapy that excises faulty exons to restore near full-length dystrophin in up to 60 percent of Duchenne patients.
Seattle-based XBOW raised $120 million in Series C funding led by DFJ Growth and Northzone, crossing the $1 billion valuation mark as it scales an AI platform that autonomously discovers and validates software vulnerabilities.
Rivian spinout Mind Robotics raises $500M Series A led by Accel and a16z at $2B valuation, challenging humanoid robot trend with AI-powered industrial automation.
Palo Alto startup Rhoda AI emerged from 18 months of stealth with a $450 million Series A at a $1.7 billion valuation, unveiling a robotics intelligence platform trained on hundreds of millions of internet videos.
MagicRNA's mRNA lipid nanoparticle therapy reprogrammed patients' own T cells inside the body, wiping out disease-driving B cells in refractory lupus patients without conventional cell manufacturing.
Two Phase 3 ARTISTRY trials show bictegravir/lenacapavir maintains viral suppression while replacing regimens of up to 11 daily pills with one tablet.